Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.

You may also be interested in...



BI Drops Flibanserin; BioSante Gets Excited

Boehringer Ingelheim shuts down development of its female desire drug due to complications in the regulatory process.

Intrinsa Needs More Safety Studies In Face Of Potential Off-Label Use

Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2

Viagra Cannot Perform In Women: Pfizer Ends Female Sexual Arousal Disorder Studies

Clinical studies "do not support a regulatory filing" in female sexual dysfunction because efficacy data were "inconclusive," the company says.

Topics

Related Companies

UsernamePublicRestriction

Register

PS005108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel